Wilmington Trust American Funds 2045 Fund Class I (WTAAFX) News

Form 8-K - Current report

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq:...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals...

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals...

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA

By Denny Jacob Milestone Pharmaceuticals shares sank 24% to $2.20 in premarket trading after it received a refusal to file letter from the Food...

Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter

By Denny Jacob Milestone Pharmaceuticals received a refusal to file letter from the Food and Drug Administration over its new drug application for...

Form 8-K - Current report

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference PR...